Course: Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial
CME Credits: 1.00
Released: 2022-06-08
Evaluating the durability of protection afforded by COVID-19 vaccines is a public health priority, with the results needed to inform policies around booster vaccinations as well as those around nonpharmaceutical interventions. We considered the mRNA-1273 P301 cohort study, which is an ongoing phase 3, randomized, placebo-controlled trial of 30,415 US adults to evaluate the efficacy and safety of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine., The vaccine efficacy (VE) against symptomatic COVID-19 was estimated at 94.1% at interim analysis and at 93.2% at completion of the blinded phase., Comparison of these 2 estimates would suggest a slight waning of VE. However, this comparison is not sensitive enough to detect the true degree of waning, because the VE estimate was obtained under the assumption that VE is constant during the period of analysis and thus represents a mean of the time-varying vaccine effect over a broad study period, weighted by when the event occurs, rather than the VE at the end of the study period.
Educational Objective
To identify the key insights or developments described in this article
View Full Course